SG Americas Securities LLC Buys Shares of 71,077 Phreesia, Inc. $PHR

SG Americas Securities LLC bought a new stake in Phreesia, Inc. (NYSE:PHR) during the 4th quarter, Holdings Channel.com reports. The fund bought 71,077 shares of the company’s stock, valued at approximately $1,203,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Phreesia by 8.3% in the third quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock valued at $134,177,000 after purchasing an additional 437,462 shares during the last quarter. New York State Common Retirement Fund grew its stake in Phreesia by 727.1% in the third quarter. New York State Common Retirement Fund now owns 136,856 shares of the company’s stock valued at $3,219,000 after purchasing an additional 120,309 shares during the last quarter. Squarepoint Ops LLC grew its stake in Phreesia by 243.6% in the second quarter. Squarepoint Ops LLC now owns 100,922 shares of the company’s stock valued at $2,872,000 after purchasing an additional 71,553 shares during the last quarter. Greenhouse Funds LLLP grew its stake in Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after purchasing an additional 557,265 shares during the last quarter. Finally, Bessemer Group Inc. grew its stake in Phreesia by 1,065.9% in the third quarter. Bessemer Group Inc. now owns 554,513 shares of the company’s stock valued at $13,043,000 after purchasing an additional 506,954 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Price Performance

Shares of PHR stock opened at $9.07 on Wednesday. Phreesia, Inc. has a fifty-two week low of $7.77 and a fifty-two week high of $32.76. The firm has a market capitalization of $550.82 million, a price-to-earnings ratio of 302.17 and a beta of 0.86. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.44 and a current ratio of 1.53. The stock’s 50-day simple moving average is $11.66 and its 200-day simple moving average is $17.04.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The business had revenue of $127.07 million for the quarter, compared to analysts’ expectations of $126.75 million. During the same quarter in the previous year, the firm posted ($0.11) EPS. Phreesia’s revenue was up 15.9% on a year-over-year basis. As a group, equities analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Phreesia

In other news, insider David Linetsky sold 6,038 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $98,781.68. Following the sale, the insider owned 223,942 shares in the company, valued at approximately $3,663,691.12. The trade was a 2.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Balaji Gandhi sold 3,829 shares of Phreesia stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total value of $43,114.54. Following the sale, the chief financial officer directly owned 146,740 shares of the company’s stock, valued at $1,652,292.40. This trade represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 70,358 shares of company stock valued at $1,123,569. Insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Needham & Company LLC cut their target price on Phreesia from $35.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Canaccord Genuity Group cut their target price on Phreesia from $33.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $16.00 target price (down from $24.00) on shares of Phreesia in a research note on Tuesday, March 31st. BMO Capital Markets cut their target price on Phreesia from $32.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Finally, Royal Bank Of Canada initiated coverage on Phreesia in a research note on Friday, January 9th. They set a “moderate buy” rating and a $26.00 price target on the stock. Twelve investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Phreesia has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.